NDAINJECTIONINJECTABLE
Approved
Oct 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
PROHANCE MULTIPACK (gadoteridol) by Bracco is magnetic resonance contrast activity [moa]. Approved for paramagnetic contrast agent [epc]. First approved in 2003.
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROHANCE MULTIPACK is a paramagnetic contrast agent containing gadoteridol, administered by injection to enhance magnetic resonance imaging (MRI) visibility of tissues and blood vessels. It works by altering the magnetic properties of nearby water molecules, improving image contrast during diagnostic imaging procedures. This injectable formulation is used across multiple MRI applications to aid in clinical diagnosis.
LOE Approaching
As a mature contrast agent approaching loss of exclusivity, the brand team is likely operating in defensive/transition mode with reduced headcount and focus on cost optimization.
Mechanism of Action
Magnetic Resonance Contrast Activity
Pharmacologic Class:
Paramagnetic Contrast Agent
Indications (1)
Clinical Trials (1)
SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study
Started Aug 2007
165 enrolled
Brain Metastases
Career Relevance
Professionals working on PROHANCE MULTIPACK are primarily engaged in defensive brand management and commercial optimization as the product approaches loss of exclusivity. This role offers limited growth potential but provides valuable experience in mature product lifecycle management, generic competition strategy, and cost-based selling in the diagnostic imaging space.
Worked on PROHANCE MULTIPACK at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.